Global X Video Games & Esports ETF HERO
27.92 USD +1.26 (+4.71%)
At closeNov 4, 2026, 4:00 PM EST
27.92 0.00 -0.01%
After hours · Nov 4, 4:00 PM ET
27.23 Day range 27.93
23.46 52-week range 32.50
- YTD
- -6.17%
- 1 year
- -13.25%
- Market cap
- 137.05M
- EPS (ttm)
- 1.54
- P/E ratio
- 18.13
- YTD return
- -6.17%
- 1-year return
- -13.25%
- Volume
- 12.36K
- Avg volume
- 17.29K
- Open
- 27.23
- Previous close
- 26.67
- Day's range
- 27.23 – 27.93
- 52-week range
- 23.46 – 32.50
3M +1.84 (+7.05%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 23.88
- 200-day average
- 22.06
About Global X Video Games & Esports ETF
The fund invests at least 80% of its total assets in the securities of the underlying index and in American Depositary Receipts ("ADRs") and Global Depositary Receipts ("GDRs") based on the securities in the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from increased consumption related to video games and esports. It is non-diversified.
News
Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials Transcript 
Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials 
106,976 Global X Video Games & Esports ETF $HERO Shares Bought by Envestnet Asset Management Inc. 
AARD DEADLINE NOTICE: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026 
AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Fraud Class Action 
Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline 
Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately 
Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline 
4 Battle-Tested Consumer Staples Stocks That Keep Raising Their Dividends 
Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline
Your note
Sign in to keep a note on HERO — it syncs with the Stock Master app.